Pharmaceutical
|
Andrew Witty, global chief executive officer of GlaxoSmith-Kline Plc, said that patented drugs were often too expensive, and the ''cost of failure'' has pushed up drug prices to exorbitant levels. He was speaking in forum attended by CEOs of major pharmaceutical companies in India. Witty said that companies need to find fresh solutions to tackle issues like affordability, access, escalating research costs and declining productivity rather than rely on "25-year-old" models.
He said that the high cost of drug discovery was "unacceptable", and urged the industry "to fail less often
|
|
Jubilant signs US$ 70 million deal for contract manufacturing for US pharma company
Publish date: 14 Sep 2011 09:06:00 PM
Jubilant Life Sciences announced today that its subsidiary, Jubilant HollisterStier, a leading contract manufacturer in North America has entered into a multi year contract with a leading US pharma company to manufacture a prominent over the counter (OTC) women health and personal care product at its Montreal facility in North America. This is a 'take or pay' contract with a minimum quantity commitment and has a total value of over US $ 70 million for a period of over 4 years with a possibility of extension for another 2 years for a higher quantity. The production of the product under this agr
|
DRDO launches herbal care product for leucoderma
Publish date: 08 Sep 2011 08:15:23 PM
Lukoskin, a herbal product for Leucoderma developed by DRDO, was launched by Dr. W. Selvamurthy, Distinguished Scientist & Chief Controller Research & Development (Life Science & International Cooperation) in New Delhi, yesterday. The product will be a boon for the patients of Leucoderma and is backed by extensive R&D work by the scientists of Defence Institute of Bio-energy Research (DIBER) (formerly Defence Agricultural Research Laboratory), Haldwani. DIBER, a DRDO laboratory has carried out extensive work in the
|
Lupin launches generic equivalent of Lotrel after getting approval from USFDA
Publish date: 06 Jul 2011 10:18:14 AM
Lupin Pharmaceuticals, Inc. (LPI), U.S. subsidiary of India based Lupin Limited, has been granted final approval by the United States Food and Drugs Administration for the company's abbreviated new drug application (ANDA) for Amlodipine / Benazepril capsules.
As per IMS health sales data the total market size of this formulation is near about US $ 1.1 billion. It is used for treating hypertension.
|
|
|
|
|
|
|
|
|
See news archives
|
|
|
|
 |
|
Economy
|
|
|
 |
|
Markets
|
|
|
 |
|
Companies
|
|
|
 |
|
Lifestyle
|
|
|
|